(BMS) has entered into a definitive merger agreement to acquire via a cash and stock transaction with an equity value of $74bn; Celgene shares have been valued at $102.43 per share.
The boards of directors of both companies have approved the deal.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAccording to the agreement, Celgene shareholders will receive one BMS share, the closing price of BMS stock was $52.43 on 2 January this year, and $50 in cash per share.
BMS expects a global, speciality biopharma company to be created with a particular focus on cancer, inflammation and immunologic diseases and cardiovascular diseases.
The new company will have a product portfolio comprising of nine products with more than $1bn in annual sales, six near-term launch opportunities with more than $15bn revenue potential and 50 high potential assets in the early stage pipeline offering positive growth.
BMS shareholders are expected to own 69% of the combined company, while Celgene shareholders will own the remaining 31%.
BMS CEO and chairman Giovanni Caforio said: 鈥淭ogether with Celgene, we are creating an innovative biopharma leader, with leading franchises and a deep and broad pipeline that will drive sustainable growth and deliver new options for patients across a range of serious diseases.鈥�
鈥淎s a combined entity, we will enhance our leadership positions across our portfolio, including in cancer and immunology and inflammation. We will also benefit from an expanded early- and late-stage pipeline that includes six expected near-term product launches.
鈥淭ogether, our pipeline holds significant promise for patients, allowing us to accelerate new options through a broader range of cutting-edge technologies and discovery platforms.鈥�
Celgene chairman and CEO Mark Alles said: 鈥淐ombining with Bristol-Myers Squibb, we are delivering immediate and substantial value to Celgene shareholders and providing them meaningful participation in the long-term growth opportunities created by the combined company.
BMS expects the rate of return from this acquisition o be in excess of both its and Celgene鈥檚 cost capital and a more than 40% accretive of BMS鈥� earnings per share on a standalone basis in the first full year.
